Monte Rosa soars after $5.7 billion licensing deal with Novartis

Monte Rosa Therapeutics

15/09/2025 15:37

Updates

** Shares of Monte Rosa Therapeutics GLUE.O jump 35.6% to $6.52

** Stock set for its biggest one-day pct. gain in over 10 months, if gains hold

** Company says it has entered into an agreement to collaborate with Swiss drugmaker Novartis NOVN.S to develop drugs for immune-mediated diseases

** The deal includes an upfront payment of $120 million to Monte Rosa, with the company eligible for a total of up to $5.7 billion in milestones and option payments across programs

** Wedbush analyst Robert Driscoll says the deal represents additional validation of Monte Rosa's molecular glue degrader discovery platform from an existing large‑pharma partner

 ** U.S.-listed shares of Novartis down 1% at $122.81

** Including session move, GLUE down 6.6%, NVS up 26% YTD

(Reporting by Siddhi Mahatole and Kamal Choudhury)

((siddhi.mahatole@thomsonreuters.com))